- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05295927
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
May 8, 2023 updated by: Janssen Research & Development, LLC
A Phase 1b Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone or Apalutamide in mCRPC (ARES: Androgen Receptor Eradication Study)
The purpose of this study is to determine safety, including dose limiting toxicities, and the recommended phase 2 dose (RP2D) of EPI-7386 in separate combinations with (a) abiraterone acetate plus prednisone or prednisolone (AAP) and (b) apalutamide (dose-finding) and to determine the antitumor activity of EPI-7386 in separate combinations with (a) AAP and (b) apalutamide (dose-expansion).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2V 1P9
- Prostate Cancer Centre
-
-
-
-
Maryland
-
Towson, Maryland, United States, 21204
- Chesapeake Urology Research Associates
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- GU Research Network
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Carolina Urologic Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically confirmed prostate adenocarcinoma
- Must be able to continue Gonadotropin-releasing hormone agonist (GnRHa) during the study if not surgically castrate
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1, or 2
- Must be able to swallow oral medicines
- Contraceptive use by men (and female partners of men enrolled in the study who are of childbearing potential or are pregnant) (birth control) use should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies
- Willing and able to adhere to the prohibitions and restrictions specified in this protocol
Exclusion Criteria:
- Known central nervous system (CNS) metastases
- Non-metastatic castration-resistant prostate cancer (CRPC) (biochemical or locoregional disease only) is excluded from trial participation
- Evidence of predominant neuroendocrine/small cell carcinoma features in archival or baseline tumor biopsy specimen(s)
- Symptomatic or impending spinal cord compression, except if participant has received definitive treatment and demonstrates evidence of clinically stable disease
- Known disorder affecting gastrointestinal absorption
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A: EPI-7386 + Abiraterone Acetate Plus Prednisone (AAP)
Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive EPI-7386 + AAP to determine the recommended phase 2 dose (RP2D) dose of EPI-7386 in combination with AAP in dose finding portion of the study.
In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with AAP.
|
EPI-7386 will be administered orally once daily.
Abiraterone Acetate will be administered orally once daily.
Prednisone or Prednisolone will be administered orally twice daily.
|
Experimental: Group B: EPI-3786 + Apalutamide
Participants with mCRPC will receive EPI-7386 + apalutamide to determine RP2D dose of EPI-7386 in combination with apalutamide in dose finding portion of the study.
In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with apalutamide.
|
EPI-7386 will be administered orally once daily.
Apalutamide will be administered orally once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events (AEs)
Time Frame: Up to 3 Years 3 Months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
|
Up to 3 Years 3 Months
|
Number of Participants with AEs by Severity
Time Frame: Up to 3 Years 3 Months
|
Number of participants with AEs by severity will be reported.
|
Up to 3 Years 3 Months
|
Number of Participants with Dose-limiting Toxicities (DLT)
Time Frame: Up to 28 days of Cycle 1 (each cycle of 28 days)
|
The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.
|
Up to 28 days of Cycle 1 (each cycle of 28 days)
|
Composite Response Rate
Time Frame: At 12 weeks
|
Composite response rate at 12 weeks, defined as either 90 percent (%) reduction in prostate-specific antigen (PSA) level from baseline (PSA-90), or objective response (confirmed per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) in participants with measurable disease, or both at 12 weeks.
|
At 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Serum Concentration (Cmax) of EPI-7386 and Abiraterone
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Cmax is defined as the maximum observed serum concentration of EPI-7386 and abiraterone.
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Time to Reach Maximum Observed Serum Concentration (Tmax) of EPI-7386 and Abiraterone
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Tmax is defined as the time to reach maximum observed serum concentration of EPI-7386 and abiraterone.
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Area Under the Curve From Time Zero to tau (AUC[0-tau]) of EPI-7386 and Abiraterone
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
AUC(0-tau) is defined as area under the curve from time 0 to tau hours post dose of EPI-7386 and abiraterone.
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Minimum Observed Serum Concentration (Cmin) of EPI-7386 and Abiraterone
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Cmin is the minimum observed serum concentration of EPI-7386 and abiraterone.
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Observed Accumulation Index Based on Cmax (ARCmax) of EPI-7386 and Abiraterone
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
The observed accumulation ratio for Cmax, determined after multiple dose administration of EPI-7386 and abiraterone (Cycle[C] 2 Day[D] 1/C1D1 and C3D1/C1D1).
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Accumulation Ratio for AUCtau (AR AUCtau) of EPI-7386 and Abiraterone
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
The observed accumulation ratio for AUCtau, determined after multiple dose administration of EPI-7386 and abiraterone (C2D1/C1D1 and C3D1/C1D1).
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Maximum Observed Serum Concentration (Cmax) of EPI-7386 and Apalutamide
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Cmax is defined as the maximum observed serum concentration of EPI-7386 and apalutamide.
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Time to Reach Maximum Observed Serum Concentration (Tmax) of EPI-7386 and apalutamide
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Tmax is defined as the time to reach maximum observed serum concentration of EPI-7386 and apalutamide.
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Area Under the Curve From Time Zero to tau (AUC[0-tau]) of EPI-7386 and Apalutamide
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
AUC(0-tau) is defined as area under the curve from time 0 to tau hours post dose of EPI-7386 and apalutamide.
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Minimum Observed Serum Concentration (Cmin) of EPI-7386 and Apalutamide
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Cmin is the minimum observed serum concentration of EPI-7386 and apalutamide.
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Observed Accumulation Index Based on Cmax (ARCmax) of EPI-7386 and Apalutamide
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
The observed accumulation ratio for Cmax, determined after multiple dose administration EPI-7386 and apalutamide (C2D1/C1D1 and C3D1/C1D1).
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Accumulation Ratio for AUCtau (AR AUCtau) of EPI-7386 and Apalutamide
Time Frame: Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
The observed accumulation ratio for AUCtau, determined after multiple dose administration EPI-7386 and Apalutamide (C2D1/C1D1 and C3D1/C1D1).
|
Day 1 of each cycle up to 3 cycles (each cycle of 28 days)
|
Serum Prostate-Specific Antigen (PSA)
Time Frame: Up to 3 Years 3 Months
|
Serum PSA concentration will be measured.
|
Up to 3 Years 3 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 23, 2022
Primary Completion (Actual)
September 30, 2022
Study Completion (Actual)
September 30, 2022
Study Registration Dates
First Submitted
March 24, 2022
First Submitted That Met QC Criteria
March 24, 2022
First Posted (Actual)
March 25, 2022
Study Record Updates
Last Update Posted (Actual)
May 9, 2023
Last Update Submitted That Met QC Criteria
May 8, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Prednisolone
- Prednisone
- Abiraterone Acetate
Other Study ID Numbers
- CR109122
- 81712917PCR2001 (Other Identifier: Janssen Research & Development, LLC)
- 2022-000946-14 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
Clinical Trials on EPI-7386
-
ESSA PharmaceuticalsRecruitingProstate CancerCanada, United States, Australia
-
ESSA PharmaceuticalsRecruitingProstate CancerUnited States, Canada
-
Pedro Barata, MD, MScESSA Pharma Inc.Not yet recruitingProstate Cancer | Prostate Adenocarcinoma | Metastatic Hormone-sensitive Prostate Cancer (mHSPC)United States
-
Exosome Diagnostics, Inc.CompletedUrologic CancerUnited States, Germany
-
University of California, Los AngelesUniversity of North Carolina, Chapel Hill; University of California, Irvine; Florida... and other collaboratorsRecruitingHIV InfectionsUnited States
-
Epigenomics, IncRecruitingColorectal Neoplasms | Colorectal CancerUnited States
-
Yale UniversityEdison Pharmaceuticals Inc; Rembrandt FoundationCompleted
-
Epigenomics, IncCompleted
-
ESSA PharmaceuticalsTerminatedGenital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, MaleUnited States, Canada
-
Walter Reed Army Medical CenterCompleted